SERPINx is currently expanding its universal platform technology around modifying serpins as well as developing its lead compound SPx-001 as a gene therapy for Heriditary Angioedema, Colitis and Thrombosis (preclinical proof-of-concept stage). Additional therapeutic candidates are currently being identified and further developed.
SERPINx has filed a broad patent application for “Modified serpins for the treatment of bradykinin-mediated disease (WO 2019/154044 A1).
SERPINx is currenty seeking further seed & series A funding to boost the development of Spx-001 as well as further development of our universal platform technology. SERPINx is actively seeking strategic collaborations with biotech/pharmaceutical companies in order to enter into license deals for specific therapeutic candidates. Clinical development costs for these programs will most likely be covered by substantial milestone payments from collaborating pharmaceutical companies, whereas additional financial VC funding is required to facilitate its position in strategic collaborative research & development projects with our clients.